RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of “Hold” from Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has received a consensus rating of “Hold” from the nine research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $4.00.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of RAPT Therapeutics in a research report on Monday, March 10th.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently bought and sold shares of RAPT. Medicxi Ventures Management Jersey Ltd bought a new position in RAPT Therapeutics during the 4th quarter valued at about $35,316,000. TCG Crossover Management LLC bought a new stake in shares of RAPT Therapeutics in the fourth quarter worth approximately $19,751,000. Orbimed Advisors LLC purchased a new position in shares of RAPT Therapeutics during the fourth quarter valued at approximately $20,754,000. Foresite Capital Management VI LLC bought a new position in RAPT Therapeutics during the fourth quarter valued at approximately $19,750,000. Finally, RTW Investments LP purchased a new stake in RAPT Therapeutics in the fourth quarter worth approximately $18,587,000. 99.09% of the stock is currently owned by institutional investors.

RAPT Therapeutics Stock Down 1.3 %

Shares of RAPT opened at $0.79 on Monday. The stock has a market cap of $104.35 million, a P/E ratio of -0.29 and a beta of -0.29. The business’s 50 day moving average price is $1.12 and its 200-day moving average price is $1.36. RAPT Therapeutics has a 52 week low of $0.75 and a 52 week high of $8.58.

RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, equities analysts anticipate that RAPT Therapeutics will post -2.14 EPS for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.